Kai Hsiung Chang 張凱雄 助研究員
The translational research in my laboratory is to discover molecular changes that cause treatment resistance in prostate cancer. We use the transcriptome and in-silico metabolic simulation to investigate the re-wired metabolisms during drug treatment. From the treatment-altered metabolic pathways, the actionable drug targets and disease biomarkers are identified and further validated in pre-clinical models. Over the past few years, we have characterized major metabolic reprogramming in the 2nd generation hormone therapy resistance tumors and delineated a new mechanism for the trans-differentiation of the adenocarcinoma tumor into a neuroendocrine prostate cancer (NEPC). The validation these discoveries in patients is ongoing, which holds great promise for improvement of men’s health and life quality, especially in ageing countries. Also, we try to regulate lineage switch by harnessing our discoveries of metabolic reprogramming in trans-differentiation, contributing to fulfillment of the unmet needs in regenerative medicine.
EDUCATION / 學歷
| 2004 – 2008 |
Ph.D., Pharmacology, Rutgers University/University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA |
| 2001 – 2004 |
M.S., Molecular and Cellular Biology, National Taiwan University, Taipei, Taiwan |
| 1995 – 1999 |
B.S., Biology, National Taiwan Normal University, Taipei, Taiwan |
EXPERIENCE / 經歷
| 2016/02 – present |
Assistant Investigator, Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan, Taiwan |
| 2013 – 2015 |
Research Associate, Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA |
| 2009 – 2013 |
Postdoctoral Researcher, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA |
LAB MEMBER / 研究團隊
PUBLICATIONS / 論文著作
PubMed Search
NHRI Institutional Repository國家衛生研究院機構典藏
